Do analysts rate MGRX or CCM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MGRX or CCM?

Concord Medical Services has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 14.00 -$20.64M -$1.49 N/A Concord Medical Services $65.85M 0.30 -$13.27M N/A N/A

Does the media prefer MGRX or CCM?

In the previous week, Mangoceuticals had 2 more articles in the media than Concord Medical Services. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for Concord Medical Services. Mangoceuticals' average media sentiment score of 0.63 beat Concord Medical Services' score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Concord Medical Services 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MRAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or MGRX more profitable?

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Mangoceuticals -4,639.13% -112.00% -104.96%

Does the media refer more to MRAI or MGRX?

In the previous week, Mangoceuticals had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for Marpai. Marpai's average media sentiment score of 0.74 beat Mangoceuticals' score of 0.63 indicating that Marpai is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BRTX or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BRTX or MGRX?

In the previous week, Mangoceuticals had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.72 beat Mangoceuticals' score of 0.63 indicating that Biorestorative Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMGL or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, BMGL or MGRX?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.38 -$9.50M N/A N/A Mangoceuticals $460K 14.00 -$20.64M -$1.49 N/A

Do analysts prefer ACON or MGRX?

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 114.16%. Given Aclarion's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aclarion is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACON or MGRX more profitable?

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aclarion -10,320.51% -54.41% -51.71% Mangoceuticals -4,639.13% -112.00% -104.96%

Does the media favor ACON or MGRX?

In the previous week, Aclarion had 11 more articles in the media than Mangoceuticals. MarketBeat recorded 14 mentions for Aclarion and 3 mentions for Mangoceuticals. Aclarion's average media sentiment score of 0.99 beat Mangoceuticals' score of 0.63 indicating that Aclarion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mangoceuticals (MGRX) Competitors

$0.38 -0.01 (-2.09%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+3.20%)

As of 06/3/2026 07:30 PM Eastern

Compare

MGRX vs. CCM, MRAI, BRTX, BMGL, and ACON

Should you buy Mangoceuticals stock or one of its competitors? MarketBeat compares Mangoceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mangoceuticals include Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), Basel Medical Group (BMGL), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Mangoceuticals compare to Concord Medical Services?

Mangoceuticals (NASDAQ:MGRX) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Concord Medical Services has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Concord Medical Services' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Concord Medical Services	N/A	N/A	N/A

Mangoceuticals has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Concord Medical Services has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 46.5% of Concord Medical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A
Concord Medical Services	$65.85M	0.30	-$13.27M	N/A	N/A

In the previous week, Mangoceuticals had 2 more articles in the media than Concord Medical Services. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for Concord Medical Services. Mangoceuticals' average media sentiment score of 0.63 beat Concord Medical Services' score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Concord Medical Services	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Marpai?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.39	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A

In the previous week, Mangoceuticals had 2 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for Marpai. Marpai's average media sentiment score of 0.74 beat Mangoceuticals' score of 0.63 indicating that Marpai is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

49.8% of Marpai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Marpai has a beta of 4.94, meaning that its share price is 394% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Summary

Marpai beats Mangoceuticals on 9 of the 14 factors compared between the two stocks.

How does Mangoceuticals compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Biorestorative Therapies has higher earnings, but lower revenue than Mangoceuticals. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	24.02	-$14.24M	-$1.07	N/A
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mangoceuticals had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Mangoceuticals and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.72 beat Mangoceuticals' score of 0.63 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biorestorative Therapies has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Mangoceuticals beats Biorestorative Therapies on 7 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.38	-$9.50M	N/A	N/A
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A

Basel Medical Group has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

In the previous week, Mangoceuticals had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for Mangoceuticals and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.43 beat Mangoceuticals' score of 0.63 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Basel Medical Group	Positive
Mangoceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

How does Mangoceuticals compare to Aclarion?

Aclarion (NASDAQ:ACON) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Aclarion has higher earnings, but lower revenue than Mangoceuticals. Aclarion is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	107.69	-$7.23M	-$9.03	N/A
Mangoceuticals	$460K	14.00	-$20.64M	-$1.49	N/A

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 114.16%. Given Aclarion's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aclarion is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Aclarion has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aclarion had 11 more articles in the media than Mangoceuticals. MarketBeat recorded 14 mentions for Aclarion and 3 mentions for Mangoceuticals. Aclarion's average media sentiment score of 0.99 beat Mangoceuticals' score of 0.63 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclarion beats Mangoceuticals on 9 of the 16 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.58M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-0.25	17.69	22.39	24.18
Price / Sales	14.00	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	0.40	3.85	9.84	6.72
Net Income	-$20.64M	$75.85M	$3.57B	$337.19M
7 Day Performance	-22.36%	-3.99%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-83.18%	19.65%	26.49%	33.10%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	1.1203 of 5 stars	$0.38 -2.1%	N/A	-82.1%	$6.58M	$460K	N/A	3
CCM Concord Medical Services	0.4493 of 5 stars	$5.22 +6.5%	N/A	-37.6%	$22.66M	$65.85M	N/A	970	Short Interest Increase Gap Down
MRAI Marpai	N/A	$0.70 -8.9%	N/A	-61.9%	$17.65M	$34.87M	N/A	150	High Trading Volume
BRTX Biorestorative Therapies	1.2523 of 5 stars	$0.51 +5.4%	N/A	-80.9%	$12.82M	$360K	N/A	7	Short Interest Decrease
BMGL Basel Medical Group	0.9225 of 5 stars	$0.61 +4.8%	N/A	-87.1%	$11.52M	$8.90M	N/A	36	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BRTX, BMGL, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Summary

How does Mangoceuticals compare to Marpai?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BRTX, BMGL, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Is MGRX or CCM more profitable?

Which has more risk & volatility, MGRX or CCM?

Do analysts rate MGRX or CCM?

Do institutionals and insiders hold more shares of MGRX or CCM?

Which has higher valuation & earnings, MGRX or CCM?

Does the media prefer MGRX or CCM?

Summary

How does Mangoceuticals compare to Marpai?

Which has better earnings and valuation, MRAI or MGRX?

Does the media refer more to MRAI or MGRX?

Do insiders & institutionals hold more shares of MRAI or MGRX?

Which has more risk & volatility, MRAI or MGRX?

Do analysts prefer MRAI or MGRX?

Is MRAI or MGRX more profitable?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Is BRTX or MGRX more profitable?

Which has higher valuation and earnings, BRTX or MGRX?

Do analysts prefer BRTX or MGRX?

Does the media refer more to BRTX or MGRX?

Which has more risk and volatility, BRTX or MGRX?

Do institutionals and insiders hold more shares of BRTX or MGRX?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Do insiders & institutionals have more ownership in BMGL or MGRX?

Is BMGL or MGRX more profitable?

Which has preferable valuation & earnings, BMGL or MGRX?

Which has more risk and volatility, BMGL or MGRX?

Does the media favor BMGL or MGRX?

Do analysts recommend BMGL or MGRX?

Summary

How does Mangoceuticals compare to Aclarion?

Which has stronger valuation and earnings, ACON or MGRX?

Do analysts prefer ACON or MGRX?

Is ACON or MGRX more profitable?

Which has more volatility & risk, ACON or MGRX?

Do insiders and institutionals believe in ACON or MGRX?

Does the media favor ACON or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools